arrow
N

Nigel Garrett

University of Cape Town
H指数:53
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

mRNA-1273 SARS-CoV-2 vaccination in people with HIV: an immune correlates analysis of CD4 + T cell responses in the multicenter CoVPN 3008 observational study

mRNA-1273 SARS-CoV-2疫苗接种在HIV感染者中的免疫相关分析:多中心CoVPN 3008观察性研究中CD4+ T细胞反应

2026-09-280
OAAI
Acceptability and perspectives on clinic-based urine tenofovir testing for antiretroviral therapy adherence monitoring: qualitative findings from a randomized controlled trial in South Africa

对基于诊所的尿液替诺福韦检测用于抗逆转录病毒疗法依从性监测的接受度和前景:来自南非一项随机对照试验的定性研究结果

2026-05-010
PRE
IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial

IgG和Fc受体基因变异与DNA和蛋白质候选HIV疫苗试验中的功能抗体反应相关

2025-11-020
OAAI
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV

中和抗体和结合抗体是CoVPN 3008研究中HIV感染者COVID-19风险的相关因素。

2025-10-060
OAAI
Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial

SARS-CoV-2变异株抗体反应的免疫相关性分析:ENSEMBLE疫苗有效性试验

2025-09-290
OAAI
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort study

非洲地区人群中SARS-CoV-2感染康复者的中和抗体应答随时间变化:一项队列研究

2025-09-110
OAAI
Africa is an Essential Partner in the Research and Development of an HIV Vaccine

非洲是HIV疫苗研究与开发的重要合作伙伴

2025-09-010
PRE
Uptake and 24-month Outcomes of Dolutegravir- Versus Lopinavir-based Second-line Antiretroviral Therapy for People With HIV in South Africa: A Retrospective Cohort Study and Emulated Target Trial

南非人群中HIV患者中,度鲁特格拉韦与洛匹那韦为基础的二线抗逆转录病毒疗法的使用及24个月结局:一项回顾性队列研究和模拟目标试验

2025-09-010
OAAI
Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults

疟原虫恶性疟原虫寄生血症不会降低HIV感染者接种mRNA COVID-19加强疫苗后的中和抗体反应

2025-08-010
OAAI
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women

与固定剂量相比,基于体重的CAP256V2LS(一种用于女性HIV预防的广谱中和抗体)的群体药代动力学研究

2025-06-010
OAAI
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+T cell responses among 13 HIV vaccine trials

一种多价的DNA初始免疫与匹配的多价蛋白/GLA-SE加强方案的组合,在13项HIV疫苗试验中诱发了最强大且广泛的IgG和IgG3 V1V2结合抗体以及CD4+T细胞反应。

2025-04-070
OAAI
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
2024-03-112
OAAI
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
2023-11-093
OAAI